PDS Biotechnology (PDSB) announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at the 12th Annual Meeting of the International Cytokine & Interferon Society in Seoul, South Korea.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- Biotech Alert: Searches spiking for these stocks today
- PDS Biotechnology’s Versamune® HPV Shows Promise in Phase 2 Trial
- PDS reports updated data from the IMMUNOCERV Phase 2 clinical trial
- PDS Biotech Advances with Promising Versamune® HPV Trial Results
- PDS Biotechnology announces updates data from VERSATILE-002 trial